Top Markets
Coin of the day
Sunshine Biopharma, Inc. Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc.

SBFM
Rang in aandelen #39262
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of... Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Aandeelprijs
$1.16
Laatst gesynchroniseerd: 2026-07-31
Marktkapitalisatie
$580.69K
Verandering (1 dag)
-5.69%
Verandering (1 jaar)
-92.32%
Land
US
Handel Sunshine Biopharma, Inc. (SBFM)

Categorie

EPS voor Sunshine Biopharma, Inc. (SBFM)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Sunshine Biopharma, Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Sunshine Biopharma, Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten